Safety and Effectiveness of Adding Either an HIV Vaccine, Interleukin-2, or Both to a Patient's Anti-HIV Drug Combination
Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if adding an HIV vaccine (ALVAC-HIV vCP1452), IL-2
(interleukin-2, a protein found in the blood that helps boost the immune system), or both to
anti-HIV-drug therapy is safe, tolerable, and effective in controlling viral load (level of
HIV in the body). (This study has been changed to clarify drug name.) Anti-HIV drugs can help
reduce a patient's viral load. However, HIV can still remain in CD4 cells (cells of the
immune system that help fight infection). Combining an HIV vaccine, IL-2, or both with
anti-HIV drugs may help reduce the number of HIV-infected cells.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)